Click to read
the new issue

April 2014
Go back
  • Novartis wins new OK for eye drug Lucentis in Europe

    June 07, 2011

    Novartis has received clearance in Europe to market its eye drug Lucentis for macular oedema secondary to retinal vein occlusion, a disease than can cause severe damage to the retina, visual impairment and ultimately blindness.

    Full story

  • NICE endorses Allergan's eye implant Ozurdex

    June 07, 2011

    Allergan will no doubt be breathing a sigh of relief after cost regulators published final draft guidance endorsing its eye implant Ozurdex for use in National Health Service patients with macular oedema.

    Full story

  • NICE asks Allergan for more data on Ozurdex

    February 08, 2011

    Cost regulators for the National Health Service in England and Wales have asked Allergan to provide more data on its macular oedema eye implant Ozurdex, particulary on how it compares to Roche/Genentech's Avastin.

    Full story

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. Next page


Head-to-Head Video


Website Search

Search News Search Magazine